Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease.

Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, Tan X, Ye S.

Circ Cardiovasc Genet. 2014 Feb;7(1):43-8. doi: 10.1161/CIRCGENETICS.113.000299. Epub 2014 Jan 6.

2.

[Total cholesterol mediates the effect of ABO blood group on coronary heart disease].

Gong P, Li S, Hu L, Luo S, Li J, Jiang H.

Zhonghua Xin Xue Guan Bing Za Zhi. 2015 May;43(5):404-7. Chinese.

PMID:
26419984
3.

High density lipoprotein cholesterol low serum level as the only risk factor in male patients with coronary heart disease.

Alessandri C, Basili S, Peverini F, Barsi R, Paradiso M, Coppotelli L, Violi F, Cordova C.

Clin Ter. 1992 Aug;141(8):109-14.

PMID:
1395453
4.

[Prevalence of cardiovascular risk factors in coronary heart disease patients with different low-density lipoprotein phenotypes].

Slapikas R, Luksiene D, Slapikiene B, Babarskiene MR, Grybauskiene R, Linoniene L.

Medicina (Kaunas). 2005;41(11):925-31. Lithuanian.

5.

Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease.

Isaacs A, Willems SM, Bos D, Dehghan A, Hofman A, Ikram MA, Uitterlinden AG, Oostra BA, Franco OH, Witteman JC, van Duijn CM.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2233-9. doi: 10.1161/ATVBAHA.113.301236. Epub 2013 Jun 13.

6.
7.

A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.

Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N.

Indian Heart J. 2003 May-Jun;55(3):234-40.

PMID:
14560932
8.

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2008 Feb 19;51(7):724-30. doi: 10.1016/j.jacc.2007.10.038.

9.

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

N Engl J Med. 1999 Aug 5;341(6):410-8.

10.

Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.

Wilt TJ, Rubins HB, Collins D, O'Connor TZ, Rutan GH, Robins SJ.

Arch Intern Med. 1996 Jun 10;156(11):1181-8.

PMID:
8639012
11.

Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease.

Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, Geshi E, Katagiri T.

Am Heart J. 2002 Dec;144(6):1026-35.

PMID:
12486427
12.

Association between periodontal disease and acute myocardial infarction.

Emingil G, Buduneli E, Aliyev A, Akilli A, Atilla G.

J Periodontol. 2000 Dec;71(12):1882-6.

PMID:
11156045
14.

LDL molecular size as risk factor in coronary artery disease.

Kozma L, Fodor J, Chockalingam A, Sussex B.

Acta Med Hung. 1992-1993;49(1-2):65-77.

PMID:
1296188
15.

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.

Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB.

N Engl J Med. 2005 Jul 7;353(1):46-57.

16.

Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.

Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, Kanno T, Saito Y.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):662-6.

17.

Wives of patients with acute myocardial infarction are at an increased risk of developing coronary artery disease.

Papamichael Ch, Zampelas A, Cimponerio A, Adamopoulos PN.

J Cardiovasc Risk. 2002 Feb;9(1):49-52.

PMID:
11984217
18.

Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).

Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.

Am J Cardiol. 2009 Jan 1;103(1):41-5. doi: 10.1016/j.amjcard.2008.08.033. Epub 2008 Oct 10.

PMID:
19101227
19.

Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction.

Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH.

N Engl J Med. 1993 Dec 16;329(25):1829-34.

20.

Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction.

Mahajan N, Ference BA, Arora N, Madhavan R, Bhattacharya P, Sudhakar R, Sagar A, Wang Y, Sacks F, Afonso L.

Am J Cardiol. 2012 Jun 15;109(12):1694-9. doi: 10.1016/j.amjcard.2012.02.010. Epub 2012 Mar 31.

PMID:
22465317

Supplemental Content

Support Center